NASDAQ : CLYD
Celldex Therapeutics, Inc. — Financial statements
United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Selling, General & Admin | 1.64M | 1.64M |
| Research & Development | 13.19M | 13.19M |
| Operating Expenses | 14.83M | 14.83M |
| Operating Income | -14.83M | -14.83M |
| Interest Expense | -131.00K | -131.00K |
| Other Non Operating Income (Expenses) | -3.40M | -3.40M |
| EBT Excluding Unusual Items | -18.37M | -18.37M |
| Other Unusual Items | 1.36M | 1.36M |
| Pretax Income | -17.00M | -17.00M |
| Net Income | -17.00M | -17.00M |
| Net Income to Common | -17.00M | -17.00M |
| Shares Outstanding (Basic) | 1.51M | 1.51M |
| Shares Outstanding (Diluted) | 1.51M | 1.51M |
| EPS (Basic) | -11.25 | -11.25 |
| EPS (Diluted) | -11.25 | -11.25 |
| EBIT | -14.83M | -14.83M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Cash & Equivalents | 220.00K | 220.00K |
| Cash & Short-Term Investments | 220.00K | 220.00K |
| Prepaid Expenses | 3.07M | 3.07M |
| Total Current Assets | 3.29M | 3.29M |
| Other Long-Term Assets | 726.00K | 726.00K |
| Total Assets | 4.02M | 4.02M |
| Accounts Payable | 912.00K | 912.00K |
| Accrued Expenses | 4.56M | 4.56M |
| Total Current Liabilities | 5.48M | 5.48M |
| Long-Term Debt | 1.48M | 1.48M |
| Other Long-Term Liabilities | 20.35M | 20.35M |
| Total Liabilities | 27.30M | 27.30M |
| Retained Earnings | -36.05M | -36.05M |
| Total Common Equity | -36.05M | -36.05M |
| Shareholders' Equity | -23.28M | -23.28M |
| Total Liabilities & Equity | 4.02M | 4.02M |
| Total Debt | 1.48M | 1.48M |
| Net Cash (Debt) | -1.26M | -1.26M |
| Net Cash Per Share | -0.83 | -0.83 |
| Filing Date Shares Outstanding | 40.85M | 40.85M |
| Total Common Shares Outstanding | 40.85M | 40.85M |
| Working Capital | -2.18M | -2.18M |
| Book Value Per Share | -0.88 | -0.88 |
| Tangible Book Value | -36.05M | -36.05M |
| Tangible Book Value Per Share | -0.88 | -0.88 |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Debt / Equity Ratio | -0.06 | -0.06 |
| Net Debt / Equity Ratio | -0.05 | -0.05 |
| Quick Ratio | 0.04 | 0.04 |
| Current Ratio | 0.60 | 0.60 |
| Return on Capital Employed (ROCE) | 1,018.80% | 1,018.80% |